BRAF and colorectal cancer: Thus, the BRAF-mutation-like 58-gene signature would be an effective biomarker than sequencing BRAF p.V600E alone to select both actual BRAF mutation carriers and BRAF wild-type in the BRAF mutation-like subtype of colorectal cancer patients who may specifically benefit from Vinorelbine treatment.